Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8153632 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
Jan, 2029
(4 years from now) | |
US8980873 | CTI BIOPHARMA CORP | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9573964 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
May, 2028
(4 years from now) |
Vonjo is owned by Cti Biopharma Corp.
Vonjo contains Pacritinib Citrate.
Vonjo has a total of 3 drug patents out of which 0 drug patents have expired.
Vonjo was authorised for market use on 28 February, 2022.
Vonjo is available in capsule;oral dosage forms.
Vonjo can be used as treatment of myelofibrosis with pacritinib, use of pacritinib for inhibiting janus associated kinase 2(jak2).
Drug patent challenges can be filed against Vonjo from 28 February, 2026.
The generics of Vonjo are possible to be released after 25 March, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Treatment of myelofibrosis with pacritinib; Use of pacritinib for inhibiting janus associated kinase 2(jak2)
Dosage: CAPSULE;ORAL